CA2467269C - Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors - Google Patents

Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors Download PDF

Info

Publication number
CA2467269C
CA2467269C CA2467269A CA2467269A CA2467269C CA 2467269 C CA2467269 C CA 2467269C CA 2467269 A CA2467269 A CA 2467269A CA 2467269 A CA2467269 A CA 2467269A CA 2467269 C CA2467269 C CA 2467269C
Authority
CA
Canada
Prior art keywords
group
compound
6alkyl
independently selected
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2467269A
Other languages
English (en)
French (fr)
Other versions
CA2467269A1 (en
Inventor
Weiqin Jiang
Zhihua Sui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of CA2467269A1 publication Critical patent/CA2467269A1/en
Application granted granted Critical
Publication of CA2467269C publication Critical patent/CA2467269C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2467269A 2001-11-14 2002-11-12 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors Expired - Fee Related CA2467269C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33297701P 2001-11-14 2001-11-14
US60/332,977 2001-11-14
PCT/US2002/036117 WO2003042213A1 (en) 2001-11-14 2002-11-12 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors

Publications (2)

Publication Number Publication Date
CA2467269A1 CA2467269A1 (en) 2003-05-22
CA2467269C true CA2467269C (en) 2011-04-05

Family

ID=23300709

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2467269A Expired - Fee Related CA2467269C (en) 2001-11-14 2002-11-12 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors

Country Status (14)

Country Link
US (1) US6686349B2 (cg-RX-API-DMAC7.html)
EP (1) EP1448562B1 (cg-RX-API-DMAC7.html)
JP (1) JP4484517B2 (cg-RX-API-DMAC7.html)
CN (1) CN1280292C (cg-RX-API-DMAC7.html)
AT (1) ATE368040T1 (cg-RX-API-DMAC7.html)
CA (1) CA2467269C (cg-RX-API-DMAC7.html)
CY (1) CY1107747T1 (cg-RX-API-DMAC7.html)
DE (1) DE60221425T2 (cg-RX-API-DMAC7.html)
DK (1) DK1448562T3 (cg-RX-API-DMAC7.html)
ES (1) ES2289159T3 (cg-RX-API-DMAC7.html)
MY (1) MY128241A (cg-RX-API-DMAC7.html)
PT (1) PT1448562E (cg-RX-API-DMAC7.html)
TW (1) TWI264437B (cg-RX-API-DMAC7.html)
WO (1) WO2003042213A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629299A1 (de) * 1996-07-20 1998-01-22 Agfa Gevaert Ag Verfahren und Vorrichtung zum Aufnehmen einer Bildinformation
CA2490239C (en) * 2002-06-19 2011-05-24 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1914235A1 (en) * 2006-10-10 2008-04-23 Universite de Lille 2 Droit et Santé Chiral tetra-hydro beta-carboline derivatives and applications thereof as antiparasitic compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN110862391B (zh) * 2019-11-13 2020-09-25 株洲千金药业股份有限公司 一种他达拉非杂质g的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH625521A5 (cg-RX-API-DMAC7.html) 1976-10-15 1981-09-30 Sandoz Ag
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
TW200408640A (en) 2004-06-01
CA2467269A1 (en) 2003-05-22
MY128241A (en) 2007-01-31
TWI264437B (en) 2006-10-21
WO2003042213A1 (en) 2003-05-22
JP2005511626A (ja) 2005-04-28
DE60221425T2 (de) 2008-06-26
EP1448562B1 (en) 2007-07-25
DK1448562T3 (da) 2007-09-24
HK1069169A1 (en) 2005-05-13
JP4484517B2 (ja) 2010-06-16
DE60221425D1 (de) 2007-09-06
EP1448562A1 (en) 2004-08-25
ATE368040T1 (de) 2007-08-15
CN1615309A (zh) 2005-05-11
CN1280292C (zh) 2006-10-18
US20030144268A1 (en) 2003-07-31
ES2289159T3 (es) 2008-02-01
US6686349B2 (en) 2004-02-03
CY1107747T1 (el) 2013-04-18
PT1448562E (pt) 2007-08-31

Similar Documents

Publication Publication Date Title
EP1289985B1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
US6818646B2 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
EP1448562B1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
AU2001261167A1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
AU2010202008A1 (en) Substituted 2,4-dihydro-pyrrolo (3,4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
EP1109814B1 (en) 5-heterocyclyl pyrazolo 4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
HK1069169B (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
AU2004201386B2 (en) 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
HK1051368B (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161114